Free Republic
Browse · Search
News/Activism
Topics · Post Article

Skip to comments.

Rockier road for blood product - Northfield's Polyheme faces tighter scrutiny
Chicago Tribune ^ | December 19, 2006 | Bruce Japsen

Posted on 12/22/2006 8:57:45 PM PST by neverdem

Just when Northfield Laboratories Inc. is on the verge of finding out whether its experimental blood substitute works well enough to submit to the Food and Drug Administration for possible approval, the regulatory climate appears to have become much tougher.

Last week Northfield's primary rival in the race to get a blood substitute to market was rebuffed by advisers to the FDA, who decided against endorsing a controversial clinical trial of Biopure Corp.'s Hemopure blood substitute.

The two companies are racing to develop a potentially lucrative product that can save lives in trauma situations by carrying oxygen through the body--an improvement on the saline used during emergencies now. A blood substitute would also be easier to transport, especially to battlefields and accident scenes, and does not require the sometimes complicated matching process real blood does.

The FDA panel's vote came despite pressure from the U.S. Navy, which had agreed to run the test for Biopure, testing it on civilian trauma patients without their consent, a rare and disputed method of testing that has already been conducted by Northfield for its product, Polyheme.

While Northfield's test of Polyheme got a green light by the FDA and was completed earlier this year, there has been an outpouring of criticism of the Evanston biotech company's trial. Critics say the testing was unethical and that not enough people were notified of the test, while others say they believe Northfield's product is dangerous.

Even though Northfield's trial is finished and the company is on the verge of announcing whether it has met its endpoint before submitting the product to the FDA for possible approval, enough negative feedback on blood substitutes could doom Polyheme, industry analysts say. Northfield said it would announce results before the end of this year.

If the FDA does not order more...

(Excerpt) Read more at chicagotribune.com ...


TOPICS: Business/Economy; Culture/Society; Foreign Affairs; News/Current Events
KEYWORDS: ethics; fda; health; medicine; polyheme; science; trauma

1 posted on 12/22/2006 8:57:49 PM PST by neverdem
[ Post Reply | Private Reply | View Replies]

To: All
An Experiment in Saving Lives
2 posted on 12/22/2006 9:06:00 PM PST by neverdem (May you be in heaven a half hour before the devil knows that you're dead.)
[ Post Reply | Private Reply | To 1 | View Replies]

To: El Gato; Ernest_at_the_Beach; Robert A. Cook, PE; lepton; LadyDoc; jb6; tiamat; PGalt; Dianna; ...
Researchers find stem-cell therapy effective in targeting metastatic cancer

Silent mutations speak up

Prions removed from animal blood

FReepmail me if you want on or off my health and science ping list.

3 posted on 12/23/2006 12:59:02 PM PST by neverdem (May you be in heaven a half hour before the devil knows that you're dead.)
[ Post Reply | Private Reply | To 2 | View Replies]

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
News/Activism
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson